OXFORD, England, October 26, 2010 /PRNewswire/ -- PharmaVentures Ltd announced today that it had acted as the advisor and broker to the Indian pharmaceutical company Dr Reddy's Laboratories in its successful marketing and distribution agreement with the UK healthcare company Vitabiotics Ltd for a range of nutraceutical products. The agreement provides Dr Reddy's exclusive marketing rights in the Russian/CIS markets for two of Vitabiotics' leading products - Jointace and Dietrim. Vitabiotics will supply these products on a long-term basis from its facilities in Europe.
The engagement with Dr Reddy's utilised PharmaVentures' significant and established pharmaceutical transactions experience in the healthcare transactions sector. Dr Fintan Walton, Chief Executive, PharmaVentures said, "We are delighted to bring another successful outcome to one of our important international clients, Dr Reddy's. We are proud to have acted as advisor and broker to one of India's premier pharmaceutical companies, particularly in assisting them to achieve their business goals in the increasingly expanding Russian/CIS market."
PharmaVentures acted as advisor and broker to the Dow Chemical Corporation in the sale of its small molecule pharmaceutical manufacturing business to Dr Reddy's, under a separate agreement in 2008.
Over the past 18 years, PharmaVentures has acted as advisors to numerous pharmaceutical and biopharmaceutical clients in transactions covering the licensing, merger, acquisition, divestment and joint venture activities for companies located worldwide.
Notes to Editors:
PharmaVentures(R) (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. Its subsidiary PharmaTelevision produces the highly popular PharmaDeals(R) range of intelligence products including analysis tools and reports as well as the world's first dedicated online pharmaceutical television channel PharmaTelevision(R) (http://www.pharmatelevision.com).
Now in its 18th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.
For press enquiries, please contact: Dr Fintan Walton, CEO PharmaVentures email@example.com +44(0)1865-332700